Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• The shift from generic to personalized cancer treatment is driven by advances in molecular profiling.
• Precision therapy utilizes individual tumor biology and patient clinical data for treatment selection.

Purpose of the Study:

• To review the evolution of precision therapy in lung cancer.
• To discuss the development of targeted therapies and immune checkpoint inhibitors.
• To explore challenges and future applications of precision therapy.

Main Methods:

• Literature review of precision therapy in lung cancer.
• Analysis of molecular subset identification and targeted drug development.
• Examination of immune checkpoint inhibitor applications and clinical trial impacts.

Main Results:

• Precision therapy has advanced lung cancer treatment through molecularly targeted drugs and immunotherapies.
• Key developments include tyrosine kinase inhibitors and immune checkpoint inhibitors.
• Challenges such as acquired resistance and clinical trial design are significant.

Conclusions:

• Precision therapy has transformed lung cancer care, moving towards individualized treatment strategies.
• Ongoing research addresses resistance mechanisms and expands precision therapy applications.
• Future directions involve novel applications and refined clinical trial designs for precision oncology.